160 related articles for article (PubMed ID: 19126947)
1. Metabolic modulation as a target for heart failure treatment: current perspective.
Chenniapan S; Manchanda SC
Indian Heart J; 2007; 59(4):370-4. PubMed ID: 19126947
[No Abstract] [Full Text] [Related]
2. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure.
Gao D; Ning N; Niu X; Hao G; Meng Z
Heart; 2011 Feb; 97(4):278-86. PubMed ID: 21134903
[TBL] [Abstract][Full Text] [Related]
3. Metabolic modulation in heart failure: high time for a definitive clinical trial.
Ashrafian H; Neubauer S
Heart; 2011 Feb; 97(4):267-8. PubMed ID: 21258118
[No Abstract] [Full Text] [Related]
4. Metabolic therapy for heart failure.
Essop MF; Opie LH
Eur Heart J; 2004 Oct; 25(20):1765-8. PubMed ID: 15474689
[No Abstract] [Full Text] [Related]
5. Myocardial metabolic manipulation: a new therapeutic approach in heart failure?
O'Meara E; McMurray JJ
Heart; 2005 Feb; 91(2):131-2. PubMed ID: 15657211
[TBL] [Abstract][Full Text] [Related]
6. Trimetazidine: the future of cardiac function?
Di Napoli P; Taccardi AA
Future Cardiol; 2009 Sep; 5(5):421-4. PubMed ID: 19715405
[No Abstract] [Full Text] [Related]
7. Metabolic approach to heart failure - evidence that trimetazidine improves symptoms, left ventricular function and possibly prognosis.
Jackson G
Int J Clin Pract; 2006 Aug; 60(8):891-2. PubMed ID: 16893429
[No Abstract] [Full Text] [Related]
8. Metabolic modulation: a new therapeutic target in treatment of heart failure.
Palaniswamy C; Mellana WM; Selvaraj DR; Mohan D
Am J Ther; 2011 Nov; 18(6):e197-201. PubMed ID: 20393344
[TBL] [Abstract][Full Text] [Related]
9. Trimetazidine and cardioprotection: facts and perspectives.
Tsioufis K; Andrikopoulos G; Manolis A
Angiology; 2015 Mar; 66(3):204-10. PubMed ID: 24719262
[TBL] [Abstract][Full Text] [Related]
10. [Metabolic therapy for heart failure].
Loiacono F; Alberti L; Lauretta L; Puccetti P; Silipigni C; Margonato A; Fragasso G
Recenti Prog Med; 2014; 105(7-8):288-94. PubMed ID: 25072544
[TBL] [Abstract][Full Text] [Related]
11. Can metabolic manipulation reverse myocardial dysfunction?
Cokkinos DV
Eur Heart J; 2001 Dec; 22(23):2138-9. PubMed ID: 11913472
[No Abstract] [Full Text] [Related]
12. Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.
Dalal JJ; Mishra S
Indian Heart J; 2017; 69(3):393-401. PubMed ID: 28648439
[TBL] [Abstract][Full Text] [Related]
13. Metabolic approach in heart failure: rethinking how we translate from theory to clinical practice.
Tang WH
J Am Coll Cardiol; 2006 Sep; 48(5):999-1000. PubMed ID: 16949493
[No Abstract] [Full Text] [Related]
14. The metabolic treatment of coronary artery disease and heart failure.
Di Napoli P
Curr Pharm Des; 2009; 15(8):826. PubMed ID: 19275645
[No Abstract] [Full Text] [Related]
15. The EMIP project. European Myocardial Infarction Project.
Tognoni G
Eur Heart J; 2000 Sep; 21(18):1498-9. PubMed ID: 10973762
[No Abstract] [Full Text] [Related]
16. [A clinical experience of taurine and trimetazidine use in premenopausal women with chronic heart failure].
Sedova EM; Magnitskaia OV
Kardiologiia; 2010; 50(1):62-3. PubMed ID: 20144159
[No Abstract] [Full Text] [Related]
17. Trimetazidine: a second look. Still no efficacy in visual disorders.
Prescrire Int; 2002 Aug; 11(60):101-5. PubMed ID: 12199261
[TBL] [Abstract][Full Text] [Related]
18. [Trimetazidine in the Treatment of Chronic HeartFailure].
Zhirov IV; Osmolovskaya YF; Tereshchenko SN
Kardiologiia; 2016 Jan; 56(1):79-85. PubMed ID: 28294737
[TBL] [Abstract][Full Text] [Related]
19. [Possibilities of myocardial cytoprotection in complex treatment of patients with chronic heart failure].
Vasiuk IuA; Iushchuk EN; Shkol'nik EL; Khadzegova AB; Vit'ko NK; Vakhromeeva MN
Kardiologiia; 2006; 46(11):48-56. PubMed ID: 17159882
[TBL] [Abstract][Full Text] [Related]
20. Flosequinan for chronic heart failure?
Drug Ther Bull; 1993 Jun; 31(12):47-8. PubMed ID: 8344139
[No Abstract] [Full Text] [Related]
[Next] [New Search]
